acarbose vs repaglinide
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acarbose and repaglinide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Precose
Prandin
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes. It works best when used with diet and exercise.
Repaglinide (Prandin) helps control blood sugar in adults with type 2 diabetes. It works best when used with diet and exercise.
Acarbose is used to help control blood sugar in adults with type 2 diabetes. You should use it along with a healthy diet and regular exercise. This medicine helps to keep your blood sugar from getting too high after you eat.
Repaglinide is used to lower blood sugar in adults with type 2 diabetes. It should be used along with a healthy diet and regular exercise. This medicine is not for people with type 1 diabetes or diabetic ketoacidosis.
Acarbose slows down the digestion of carbohydrates (sugars and starches) in your body. It does this by blocking certain enzymes in your small intestine that break down carbs. This helps to prevent a sharp rise in blood sugar after meals.
Repaglinide helps your pancreas release insulin after you eat. Insulin helps move sugar from your blood into your cells. This lowers your blood sugar levels.
- • Gas
- • Diarrhea
- • Abdominal pain
- • Low blood sugar
- • Upper respiratory infection
- • Headache
- • Sinus infection
- • Joint pain
- Hypoglycaemia 269
- Nausea 203
- Blood Glucose Increased 200
- Dizziness 160
- Diarrhoea 147
- Hypoglycaemia 765
- Acute Kidney Injury 548
- Drug Interaction 418
- Diarrhoea 365
- Lactic Acidosis 364
You should not take acarbose if you have diabetic ketoacidosis or cirrhosis. Also, do not take it if you have inflammatory bowel disease, colon ulcers, or any bowel obstruction. This medicine can cause liver problems in some people. Tell your doctor right away if you develop symptoms like yellowing of the skin or eyes.
Repaglinide can cause low blood sugar (hypoglycemia). If you skip a meal, skip your dose of repaglinide to avoid low blood sugar. Do not use repaglinide with NPH-insulin. There is no proof that repaglinide lowers your risk of heart problems.
Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acarbose will harm your unborn baby. Talk to your doctor if you are breastfeeding or plan to breastfeed. It is not known if acarbose passes into breast milk.
Tell your doctor if you are pregnant or plan to become pregnant. Poorly controlled diabetes during pregnancy can harm both the mother and the baby. Repaglinide is not recommended while breastfeeding due to the risk of low blood sugar in the baby.
Also Compare, Nearby Drugs
Compare acarbose with
Compare repaglinide with
How to Read This acarbose vs repaglinide Comparison
acarbose is classified in the Alpha-Glucosidase Inhibitor drug class, while repaglinide sits within the Meglitinide class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acarbose has 979 submissions while repaglinide has 2,460. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acarbose or repaglinide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.